Skip to content
Clinical Trials – home
SpainBack to Spain

Clinical trials in Sabadell – page 119

3 741 clinical trials in Sabadell, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Sabadell at a glance
3 741
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 741 trials in Sabadell

Open in trial search

Breast cancer

Not yet recruiting

Discontinuation of anti‑HER2 therapy guided by ctDNA in patients with HER2‑positive metastatic breast cancer receiving pertuzumab and trastuzumab

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Small for dates baby

Not yet recruiting

A Phase III Study of Sildenafil to Reduce Adverse Perinatal Outcomes in Pregnant Women Carrying Small‑for‑Gestational‑Age Fetuses

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Sildenafil
  • Sponsor:Fundacio Sant Joan De Deu

Sjogren's syndrome

Not yet recruiting

A Phase 2a/b Study of DDY391 to Evaluate Efficacy, Safety and Tolerability in Adults with Sjögren's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Phase Ib/II Study of Zongertinib Combined with Ribociclib and Trastuzumab in Patients with Metastatic ER‑positive/HER2‑positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ribociclib
  • Sponsor:Solti Group

Study of VSA012 Sodium in Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Complement Inhibitor‑Naïve or Have Persistent Anemia on C5 Inhibitor Therapy

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Bisirna Therapeutics Pte. Ltd.

Study of elranatamab, mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Fundacion Pethema

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Alcoholic liver disease

Not yet recruiting

Safety and Efficacy of Efimosfermin Alfa vs Placebo in Adults with Alcohol-Related Liver Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Breast cancer+1

Not yet recruiting

Long‑term safety study of alpelisib alone or with fulvestrant in adults with breast cancer who benefited from previous alpelisib treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 210 cities in Spain

Clinical research in Sabadell

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Acute Respiratory Distress Syndrome (ARDS) and advanced lung cancer treatments. Studies evaluating new therapeutic approaches for non-small cell lung cancer, including combination therapies with immunotherapy agents.

  • Mechanical ventilation optimization
  • Combined immunotherapy approaches
  • Advanced stage cancer treatment
02 Oncology Studies

Comprehensive research into various cancer types, including bladder cancer and prostate cancer. Studies examining novel combination therapies and investigating new treatment approaches for both early-stage and metastatic conditions.

  • Immunotherapy combinations
  • Targeted therapies
  • Treatment resistance
03 Autoimmune Conditions

Groundbreaking research in autoimmune disorders including Sjögren's Syndrome and Systemic Sclerosis. Studies evaluating novel biological therapies and investigating long-term treatment outcomes for chronic conditions.

  • Biological therapy assessment
  • Long-term safety evaluation
  • Quality of life improvements
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.